ReviewBritish journal of clinical pharmacology2019
Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.
Review in British journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Medication-related osteonecrosis of the jaw in breast cancer patients: a longitudinal observational Swedish study of oral health and antiresorptive use.BMC oral health · 2026Observational
- Bone health in cancer: perspective on the use of osteoanabolic agents.Therapeutic advances in endocrinology and metabolism · 2025Review
- RANK/RANKL Signaling Pathway in Breast Development and Cancer.Advances in experimental medicine and biology · 2025Review
- RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.EMBO molecular medicine · 2023Article
- Vertebral Fractures After Denosumab Discontinuation in Breast Cancer Survivors: A Single Institution Experience.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2021Article
- Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.British journal of clinical pharmacology · 2019Review
- Drugs for the treatment of metabolic bone diseases.British journal of clinical pharmacology · 2019Article
- Pharmacology of bisphosphonates.British journal of clinical pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Potent antiresorptive drugs (bisphosphonate and denosumab) are often used to protect bone health in postmenopausal breast cancer patients. In addition, clinical trials have shown that these drugs increase disease-free survival, though the mechanism of adjuvant benefit is largely unknown. Here we review the bone health and adjuvant data for both classes of antiresorptive drugs and highlight differences in their pharmacology. Inhibition of bone resorption is vitally important to protect against osteoporotic fractures, and may also contribute to adjuvant survival benefits by making the bone microenvironment less amenable to breast cancer metastasis. After a course of therapy, stoppage of bisphosphonates yields a persistent antiresorptive effect, whereas discontinuation of denosumab causes a rebound increase in bone resorption markers and a loss of bone mineral density to baseline levels. Whether the potential adjuvant benefits of denosumab are also rapidly lost after drug discontinuation deserves further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.